Sandoz Group Ltd earnings date
Want to see CH:SDZ full AI Analyst Report?
Sandoz Group Ltd (SDZ) Q4 2023 Earnings Report
CH:SDZ Q4 2023 EPS Results
- Actual EPS
- CHF 0.82
- Consensus EPS
- CHF 0.41
- Beat/Miss
- Beat by +CHF 0.40
- One Year Ago EPS
- ―
CH:SDZ Q4 2023 Revenue Results
- Actual Revenue
- ―
- Expected Revenue
- CHF 2.06B
- Beat/Miss
- ―
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q4 2023
- Date
- 03/13/2024
- Time
- Before Open
- Conference Call
- Wednesday, March 13, 2024
Sandoz Group Ltd's next earnings date is estimated for February 17, 2027, based on past reporting schedules.
Q4 2023 Earnings Call Audio
Q4 2023 Earnings Slide Deck
Q4 2023 Earnings Call Summary
The earnings call presented a mixed picture with strong sales growth, particularly in the biosimilars segment and North American market recovery. However, the financial performance was impacted by negative free cash flow, a decline in core EBITDA margin, significant restructuring, and legal costs.
During the Sandoz Q4 2023 earnings call, the company reported a strong financial performance, exceeding sales growth guidance with a 7% increase to $9.6 billion for the year and achieving a core EBITDA of $1.7 billion, reflecting an 18.1% margin. The biosimilar segment saw significant growth, contributing 23% to total sales, up from 20% in 2022, with products like Omnitrope and the launch of Hyrimoz in the U.S. playing key roles. Despite a negative free cash flow of $234 million due to initial investments post-spin-off, Sandoz anticipates a robust cash flow increase by 2028. Looking forward to 2024, the company expects mid-single-digit net sales growth and core EBITDA margins to reach around 20%, driven by continued biosimilar momentum and operational efficiencies.
- Strong Sales GrowthFourth quarter 2023 was the strongest consecutive quarter of top line growth, with sales up 10% compared to the previous year. For the full year, sales grew 7% to $9.6 billion, with volume contributing 10 percentage points of growth.
- Biosimilars PerformanceBiosimilars were up 26% in Q4, with significant contributions from the U.S. launch of Hyrimoz and continued demand for Omnitrope. Full-year biosimilars growth was 15%, raising their share of total sales to 23%.
- North American Market RecoveryThe North American region returned to growth, increasing by 20% in Q4. This was driven by rebuilding the pipeline, strengthening customer relationships, and strong biosimilar performance.
- Strategic AcquisitionsThe acquisition of CIMERLI from Coherus was completed ahead of schedule, establishing a commercial platform in the U.S. retina market and expanding the ophthalmology portfolio.
- Sustainability InitiativesSandoz submitted a commitment letter to the SBTI, planning to set science-based carbon emission reduction targets in line with the Paris Agreement goals.
CH:SDZ Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 17, 2027 | 2026 (Q4) | 1.90- | 1.67 | ― | ― |
| Aug 05, 2026 | 2026 (Q2) | 1.481.41 | 1.2 | 17.12% (+0.21) | |
| Feb 25, 2026 | 2025 (Q4) | 1.431.67 | 1.31 | 27.36% (+0.36) | |
| Aug 07, 2025 | 2025 (Q2) | 1.011.20 | 0.92 | 30.36% (+0.28) | |
| Mar 05, 2025 | 2024 (Q4) | 1.341.31 | 0.82 | 60.61% (+0.49) | |
| Aug 08, 2024 | 2024 (Q2) | 0.820.92 | 0.99 | -6.67% (-0.07) | |
| Mar 13, 2024 | 2023 (Q4) | 0.410.82 | ― | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


